Improved tumour control probability with MRI-based prostate brachytherapy treatment planning

Acta Oncologica

Volumn 52, Issue 3, 2013, Pages 658-665

  Dinkla, Anna M ^a   Pieters, Bradley R ^a   Koedooder, Kees ^a   Van Wieringen, Niek ^a   Van Der Laarse, Rob ^a   Van Der Grient, Johan N ^a   Rasch, Coen R ^a   Koning, Caro C ^a   Bel, Arjan ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMAGE QUALITY; INTERMETHOD COMPARISON; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROSTATE VOLUME; TREATMENT PLANNING; CANCER RADIOTHERAPY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED RADIOTHERAPY; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ORGANS AT RISK; PROSTATE; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION ONCOLOGIST; SEMINAL VESICLE;

BRACHYTHERAPY; CARCINOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; ORGAN SIZE; ORGANS AT RISK; PROBABILITY; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84875184471     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.744875     Document Type: Article

References (37)

1. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Jr., Miller DW, Adams JA, et al. Comparison of conventionaldose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005;294:1233-9 (Pubitemid 41352111)
2. Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: Initial results of a randomised phase three trial. Radiother Oncol 2007;84:114-20 (Pubitemid 47284526)
3. Villeirs GM, Van VK, Vakaet L, Bral S, Claus F, De Neve WJ, et al. Interobserver delineation variation using CT versus combined CT MRI in intensity-modulated radiotherapy for prostate cancer. Strahlenther Onkol 2005;181:424-30 (Pubitemid 40956578)
4. Gao Z, Wilkins D, Eapen L, Morash C, Wassef Y, Gerig L. A study of prostate delineation referenced against a gold standard created from the visible human data. Radiother Oncol 2007;85:239-46 (Pubitemid 350160996)
5. Debois M, Oyen R, Maes F, Verswijvel G, Gatti G, Bosmans H, et al. The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. Int J Radiat Oncol Biol Phys 1999;45:857-65 (Pubitemid 29525447)
6. Smith WL, Lewis C, Bauman G, Rodrigues G, D'Souza D, Ash R, et al. Prostate volume contouring: A 3D analysis of segmentation using 3DTRUS, CT, and MR. Int J Radiat Oncol Biol Phys 2007;67:1238-47
7. Pieters BR, Geijsen ED, Koedooder K, Blank LE, Rezaie E, van der Grient JN, et al. Treatment results of PDR brachytherapy combined with external beam radiotherapy in 106 patients with intermediate- to high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2011;79:1037-42
8. Pieters BR, van der Grient JN, Blank LE, Koedooder K, Hulshof MC, de Reijke TM. Minimal displacement of novel self-anchoring catheters suitable for temporary prostate implants. Radiother Oncol 2006;80:69-72 (Pubitemid 44226436)
9. van't Riet A., Mak AC, Moerland MA, Elders LH, van der Zee W. A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: Application to the prostate. Int J Radiat Oncol Biol Phys 1997;37:731-6 (Pubitemid 27175329)
10. Van der Laarse R, Luthmann RW. Computers in brachytherapy dosimetry. In: Joslin CAF, Flynn A, Hall EJ, editors. Principles and practice of brachytherapy using afterloading systems. London: Arnold; 2001. p. 49-80
11. Moerland MA, van der Laarse R, Luthmann RW, Wijrdeman HK, Battermann JJ. The combined use of the natural and the cumulative dose-volume histograms in planning and evaluation of permanent prostatic seed implants. Radiother Oncol 2000;57:279-84
12. Dale RG. The application of the linear-quadratic model to fractionated radiotherapy when there is incomplete normal tissue recovery between fractions, and possible implications for treatments involving multiple fractions per day. Br J Radiol 1986;59:919-27 (Pubitemid 16023354)
13. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005; 44:265-76 (Pubitemid 40904130)
14. Gao M, Mayr NA, Huang Z, Zhang H, Wang JZ. When tumor repopulation starts? The onset time of prostate cancer during radiation therapy. Acta Oncol 2010;49: 1269-75
15. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;52:6-13 (Pubitemid 34041562)
16. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50: 1021-31
17. Wang JZ, Guerrero M, Li XA. How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003;55:194-203
18. Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 2003;57:391-401 (Pubitemid 37040935)
19. Carlone M, Wilkins D, Raaphorst GP. Radiobiological parameters suitable for modeling individual outcomes cannot be obtained by analyzing heterogeneous population data with homogeneous tumor control model: In regard to D'Souza et al. (Int J Radiat Oncol Biol Phys 2004;58: 1540-1548). Int J Radiat Oncol Biol Phys 2005;62:298-9 (Pubitemid 40591961)
20. Liu D, Usmani N, Ghosh S, Kamal W, Pedersen J, Pervez N, et al. Comparison of prostate volume, shape, and contouring variability determined from preimplant magnetic resonance and transrectal ultrasound images. Brachytherapy 2012; 11:284-91
21. Parker CC, Damyanovich A, Haycocks T, Haider M, Bayley A, Catton CN. Magnetic resonance imaging in the radiation treatment planning of localized prostate cancer using intra-prostatic fiducial markers for computed tomography co-registration. Radiother Oncol 2003;66:217-24 (Pubitemid 36315832)
22. De Brabandere M, Hoskin P, Haustermans K, Van den Heuvel F, Siebert FA. Prostate post-implant dosimetry: Interobserver variability in seed localisation, contouring and fusion. Radiother Oncol 2012;104:192-8
23. Rasch C, Barillot I, Remeijer P, Touw A, van HM, Lebesque JV. Definition of the prostate in CT and MRI: A multi-observer study. Int J Radiat Oncol Biol Phys 1999;43:57-66 (Pubitemid 29065832)
24. Roach M, Faillace-Akazawa P, Malfatti C, Holland J. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1996;35:1011-8 (Pubitemid 26279773)
25. Prete JJ, Prestidge BR, Bice WS, Dubois DF. Comparison of MRI- and CT-based post-implant dosimetric analysis of transperineal interstitial permanent prostate brachytherapy. Radiat Oncol Investig 1998;6:90-6 (Pubitemid 28185740)
26. Usmani N, Sloboda R, Kamal W, Ghosh S, Pervez N, Pedersen J, et al. Can images obtained with high field strength magnetic resonance imaging reduce contouring variability of the prostate? Int J Radiat Oncol Biol Phys 2011;80:728-34
27. Acher P, Rhode K, Morris S, Gaya A, Miquel M, Popert R, et al. Comparison of combined x-ray radiography and magnetic resonance (XMR) imaging-versus computed tomography-based dosimetry for the evaluation of permanent prostate brachytherapy implants. Int J Radiat Oncol Biol Phys 2008;71:1518-25
28. Petrik D, Araujo C, Kim D, Halperin R, Crook JM. Implications of CT imaging for postplan quality assessment in prostate brachytherapy. Brachytherapy 2012;11: 435-40
29. Aoki M, Yorozu A, Dokiya T. Results of a dummy run of postimplant dosimetry between multi-institutional centers in prostate brachytherapy with 125I seeds. Jpn J Radiol 2009; 27:410-5
30. Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2009;75:16-22
31. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67:327-33 (Pubitemid 46108308)
32. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: Biopsy strategy implications. Cancer 2000;89:1800-9
33. Merrick GS, Gutman S, Andreini H, Taubenslag W, Lindert DL, Curtis R, et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol 2007;52:715-23
34. D'Amico AV, Davis A, Vargas SO, Renshaw AA, Jiroutek M, Richie JP. Defining the implant treatment volume for patients with low risk prostate cancer: Does the anterior base need to be treated? Int J Radiat Oncol Biol Phys 1999;43:587-90 (Pubitemid 29107180)
35. Steenbakkers RJ, Duppen JC, Betgen A, Lotz HT, Remeijer P, Fitton I, et al. Impact of knee support and shape of tabletop on rectum and prostate position. Int J Radiat Oncol Biol Phys 2004;60:1364-72 (Pubitemid 39601853)
36. Lindsay PE, Moiseenko VV, Van DJ, Battista JJ. The influence of brachytherapy dose heterogeneity on estimates of alpha/ beta for prostate cancer. Phys Med Biol 2003;48:507-22 (Pubitemid 36322042)
37. D'Souza WD, Thames HD, Kuban DA. Dose-volume conundrum for response of prostate cancer to brachytherapy: Summary dosimetric measures and their relationship to tumor control probability. Int J Radiat Oncol Biol Phys 2004;58:1540-8 (Pubitemid 38438319)